Overview
flowchart TD
companies_pd_metabolic_interse["PD-Metabolic Intersection Companies"]
companies_pd_metabolic_interse["page"]
companies_pd_metabolic_interse -->|"related to"| companies_pd_metabolic_interse
style companies_pd_metabolic_interse fill:#81c784,stroke:#333,color:#000
companies_pd_metabolic_interse["covers"]
companies_pd_metabolic_interse -->|"related to"| companies_pd_metabolic_interse
style companies_pd_metabolic_interse fill:#81c784,stroke:#333,color:#000
companies_pd_metabolic_interse["biotechnology"]
companies_pd_metabolic_interse -->|"related to"| companies_pd_metabolic_interse
style companies_pd_metabolic_interse fill:#81c784,stroke:#333,color:#000
companies_pd_metabolic_interse["pharmaceutical"]
companies_pd_metabolic_interse -->|"related to"| companies_pd_metabolic_interse
style companies_pd_metabolic_interse fill:#81c784,stroke:#333,color:#000
style companies_pd_metabolic_interse fill:#4fc3f7,stroke:#333,color:#000
This page covers biotechnology and pharmaceutical companies developing treatments that target the intersection of metabolic dysfunction and Parkinson's disease (PD). Research has established strong epidemiological and mechanistic links between metabolic disorders (type 2 diabetes, obesity, metabolic syndrome) and Parkinson's disease risk and progression. [@diabetespd]
The metabolic-PD intersection represents a promising therapeutic approach because:
...Overview
Mermaid diagram (expand to render)
This page covers biotechnology and pharmaceutical companies developing treatments that target the intersection of metabolic dysfunction and Parkinson's disease (PD). Research has established strong epidemiological and mechanistic links between metabolic disorders (type 2 diabetes, obesity, metabolic syndrome) and Parkinson's disease risk and progression. [@diabetespd]
The metabolic-PD intersection represents a promising therapeutic approach because:
- Epidemiological link: Type 2 diabetes increases PD risk by approximately 30-40%
- Shared pathways: Insulin signaling, mitochondrial dysfunction, and neuroinflammation are common to both conditions
- Repurposing opportunity: GLP-1 receptor agonists and other metabolic drugs have established safety profiles
Key Therapeutic Approaches
GLP-1 Receptor Agonists
GLP-1 receptor agonists have emerged as the leading therapeutic class for the PD-metabolic intersection. GLP-1 receptors are expressed in the brain, and activation provides neuroprotection through multiple mechanisms:
- Anti-inflammatory effects: Modulating microglial activity and reducing neuroinflammation
- Metabolic support: Improving glucose metabolism in the brain
- Synaptic protection: Supporting synaptic plasticity and preventing dopaminergic neuron loss
- Alpha-synuclein modulation: Reducing pathological aggregation
Mitochondrial-Targeted Therapies
Metabolic dysfunction in PD is closely tied to mitochondrial impairment:
- Complex I deficiency: Documented in substantia nigra of PD patients
- Mitophagy defects: Impaired clearance of damaged mitochondria
- Oxidative stress: Consequence of mitochondrial dysfunction
Insulin Signaling Modulators
Insulin resistance in the brain is a emerging target:
- Intranasal insulin: Direct delivery to the brain
- Insulin sensitizers: Improving central insulin signaling
- AMPK activators: Enhancing cellular energy metabolism
Companies in This Space
Novo Nordisk A/S
Ticker: NASDAQ: NVO
Headquarters: Copenhagen, Denmark
Novo Nordisk is the leading developer of GLP-1 receptor agonists for neurodegenerative diseases. Their PD programs include:
| Drug | Mechanism | Phase | Status |
|------|-----------|-------|--------|
| Semaglutide | GLP-1 RA | Phase 2 | Completed |
| Semaglutide | GLP-1 RA | Phase 3 (AD) | Recruiting |
The company has leveraged its expertise in metabolic diseases to pursue neurodegenerative applications, with semaglutide (Ozempic/Wegovy) being evaluated in PD clinical trials. [@glp1pd]
Related pages:
- [Novo Nordisk](/companies/novo-nordisk)
- [GLP-1 Receptor Agonists](/therapeutics/glp-1-receptor-agonists)
Neuraly, Inc.
Headquarters: Baltimore, Maryland, USA
Neuraly is a clinical-stage biotechnology company focused on developing GLP-1 receptor agonists for neurodegenerative diseases. Their lead candidate NLY01 (Pegcreatecan) is a long-acting GLP-1R agonist designed to penetrate the blood-brain barrier.
| Drug | Mechanism | Phase | Status |
|------|-----------|-------|--------|
| NLY01 | GLP-1R agonist | Phase 2 | Completed |
NLY01 works through multiple neuroprotective pathways:
- Astrocyte modulation: Blocking conversion of astrocytes to toxic A1 phenotype
- Microglial regulation: Reducing pro-inflammatory cytokine release
- Anti-apoptotic effects: Protecting dopaminergic neurons
The Phase 2 trial in early Parkinson's disease completed in 2024. The trial demonstrated safety but did not meet its primary efficacy endpoint, informing ongoing research in this space.
Related pages:
- [Neuraly](/companies/neuraly)
- [Astrocyte PD Therapy Companies](/companies/astrocyte-pd-therapy-companies)
Eli Lilly and Company
Ticker: NYSE: LLY
Headquarters: Indianapolis, Indiana, USA
Eli Lilly has an active neuroscience program including metabolic-based approaches for neurodegenerative diseases. Their GLP-1 portfolio and broader metabolic expertise positions them as a key player in this intersection.
Lilly's approach to neurodegenerative diseases includes:
- GLP-1 receptor agonists for neuroprotection
- Metabolic pathway modulators
- Anti-amyloid and anti-tau programs
Related pages:
- [Eli Lilly](/companies/eli-lilly)
- [Alzheimer's Disease Pipeline Companies](/companies/alzheimers-disease-pipeline-companies)
Cytochrome Therapeutics
Headquarters: Cambridge, Massachusetts, USA
Cytochrome Therapeutics is developing CT-101, a first-in-class small molecule that restores mitochondrial Complex I function. The company targets the fundamental bioenergetic defect that underlies dopaminergic neuron degeneration in PD.
Rationale:
- Post-mortem studies show reduced Complex I activity in substantia nigra of PD patients
- Complex I deficiency is sufficient to cause PD-like pathology in models
- Restoring Complex I may protect remaining neurons
Related pages:
- [Cytochrome Therapeutics](/companies/cytochrome-therapeutics)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
Clene Nanomedicine
Ticker: NASDAQ: CLNN
Headquarters: Salt Lake City, Utah, USA
Clene develops CNM-Au8, a gold nanocatalytic therapeutic that addresses mitochondrial dysfunction in Parkinson's disease. The REPAIR-PD trial (NCT03815916) evaluated this approach.
Mechanism:
- Improves mitochondrial Complex I activity
- Supports neuronal energy metabolism
- Nanocatalytic approach differs from traditional antioxidants
Related pages:
- [Clene Nanomedicine](/companies/clene-nanomedicine)
- [PD Mitochondrial Dysfunction](/mechanisms/pd-mitochondrial-dysfunction)
Inhibikase Therapeutics
Ticker: NASDAQ: IKT
Headquarters: Boston, Massachusetts, USA
Inhibikase develops IkT-148009, a c-Abl tyrosine kinase inhibitor for Parkinson's disease. While not directly metabolic, c-Abl activation is induced by cellular stress including metabolic dysfunction, linking to the broader metabolic-PD intersection.
Related pages:
- [Inhibikase Therapeutics](/companies/inhibikase)
- [c-Abl in Parkinson's Disease](/mechanisms/cabl-parkinsons)
Emerging Players
Several additional companies have programs that intersect with metabolic dysfunction in PD:
| Company | Approach | Status |
|---------|----------|--------|
| Mapi Pharma | GA-GLP-1 (enhanced brain penetration) | Preclinical |
| Kallyope | Gut-brain axis modulators | Discovery |
| Axial Therapeutics | Microbiome-based approaches | Clinical |
Clinical Trial Landscape
Active GLP-1 Trials in PD (as of 2024)
| Trial ID | Drug | Company | Phase | Status |
|----------|------|---------|-------|--------|
| NCT05024240 | NLY01 | Neuraly | Phase 2 | Completed |
| NCT04875359 | Semaglutide | Novo Nordisk | Phase 2 | Completed |
Completed Trials
The field has learned from both positive and negative trial results, informing next-generation approaches:
- GLP-1 agonists show biomarker modulation consistent with neuroprotection
- Need for earlier intervention and better patient selection
- Combination approaches may be necessary
Scientific Rationale
Epidemiological Evidence
- Meta-analyses show type 2 diabetes increases PD risk by 35% [@diabetespd]
- Metabolic syndrome components correlate with PD severity
- Diabetes medications may modify PD progression
Mechanistic Overlap
Key shared pathways between metabolic disorders and PD: [@metabolism]
Insulin signaling impairment: Brain insulin resistance in both conditions
Mitochondrial dysfunction: Central to both diabetic complications and PD
Neuroinflammation: Shared inflammatory pathways
Oxidative stress: Common final pathway
Protein homeostasis: ER stress and autophagy impairmentsRelated Pages
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Parkinson's Disease Pipeline Companies](/companies/pd-pipeline-companies)
- [GLP-1 Receptor Agonists](/therapeutics/glp-1-receptor-agonists)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
- [PD Neuroinflammation](/mechanisms/pd-neuroinflammation)
- [Novo Nordisk](/companies/novo-nordisk)
- [Neuraly](/companies/neuraly)
- [Eli Lilly](/companies/eli-lilly)
References
[GLP-1 Receptor Agonists in Parkinson's Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38760092/)
[Metabolic Dysfunction in Parkinson's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35617895/)
[Type 2 Diabetes and Parkinson's Disease Risk (2020)](https://pubmed.ncbi.nlm.nih.gov/32837666/)Pathway Diagram
The following diagram shows the key molecular relationships involving PD-Metabolic Intersection Companies discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)